|Fuminori Yoshida||Representative Director and President
Chief Executive OfficerDetails
|Shigeo Kimura||Board DirectorDetails|
|Shigetoshi Matsumoto||Board Director<Outside>Details|
|Bruce David Cheson||Board Director<Outside>Details|
|Eiji Ebinuma||Board Director<Outside>Details|
|Kiyoshi Watanabe||Full-Time Audit & Supervisory Board Member<Outside>Details|
|Kesao Endo||Audit & Supervisory Board Member<Outside>Details|
|Yasuhiro Tamo||Audit & Supervisory Board Member<Outside>Details|
| Fuminori Yoshida
Representative Director and President
Chief Executive Officer
|Fuminori Yoshida established SymBio Pharmaceuticals Limited, his third company, in March of 2005 in order to address the unmet medical needs of Japanese patients; as founding President of two other major healthcare companies, Nippon BioRad Laboratories (1980) and Amgen Japan (1993), he has earned high visibility and credibility within Japan's healthcare and academic communities. Following his graduation from Gakushuin University in 1971 with a B.S. in Organic Chemistry, he went on to receive an M.S. in Molecular Biology from MIT (1973) and M.S. in Health Policy and Management from Harvard University Graduate School (1975). He possesses dual experience and expertise in the management of major Japanese and American corporations through his work for various companies in the past, such as Mitsubishi Corporation and AHS Japan, Syntex Japan (1993) as President and CEO, serving concurrently at Amgen Japan (presently, Takeda Bio Development Center Ltd.) as President and CEO, and Amgen Inc. as Corporate Vice-President for 12 years until January of 2005. He has retained a high profile within the pharmaceutical industry due to his active involvement in various conferences (e.g. keynote speaker at 1st Bio-Expo), as member of several committees sponsored by the Ministry of Science and Technology, as lecturer at several prestigious colleges (e.g. Waseda University), as author of various publications in reputable pharmaceutical business journals, and as author of two books which were subsequently published in Japan (‘Golden DNA Helix' and ‘A Story of a Biotech Pioneer'). Utilizing his extensive management experience and social network, he has assembled an exceptional management team at SymBio.|
|Shigeo Kimura graduated from Kanagawa University Faculty of Economics in 1986 and joined Squibb Corporation, currently Bristol-Myers Squibb, in the same year. After working in Sales & Oncology Marketing Divisions, Mr. Kimura was assigned to BMS Canada in 2011.
After returning to Japan in 2015, Mr. Kimura became the Head of Sales Cardiovascular, Metabolic and Immune Division and Hematology Marketing Franchise Lead in the field of Hematology and Liver. In 2016, he was appointed as Corporate Officer, serving as the head of Commercial Operations and Oncology as well. In 2019, he joined SymBio as Corporate Officer, Managing Executive Officer, CCO and Head of Japan Business Unit. In March 2020, he was also appointed as Board Director and Senior Managing Officer in addition to his roles as Corporate Officer and Head of Japan Business Unit.
|Shigetoshi Matsumoto graduated from University of Toyama Faculty of Pharmacy and Pharmaceutical Sciences in 1972, and then joined CHUGAI PHARMACEUTICAL CO., LTD. After holding various positions in Sales & Marketing related divisions, he assumed the position of General Manager of the Audit Office (2002),
At the Company, he has successively held the positions of Full-time Audit & Supervisory Board Member (2007), and Senior Advisor (2011). He became Advisor to APO PLUS STATION Co., Ltd. in 2011, and then became Senior Advisor to Protiviti LLC in 2015. He served as a member of the Audit & Supervisory Board at the Company in 2017.
He currently serves as Audit Practice Counselor, Japan Audit & Supervisory Board Members Association.
|Bruce David Cheson
|Dr. Cheson received his medical degree from Tufts University and completed his residency at University of Virginia Hospitals (1971) and fellowship at New England Medical Center Hospital (1974). Then he assumed Assistant Professor of Medicine, Hematology/Oncology of University of Utah School, University of Utah Hospital (1977), and Senior Investigator and Head of Medicine Section, National Cancer Institute, Cancer Therapy Evaluation Program (1984). He joined Georgetown University Hospital, Lombardi Comprehensive Cancer Center as Deputy Chief, Hematology-Oncology, Head of Hematology (2002), and became Frank M. Ewing Foundation Chair in Hematology-Oncology since 2018, Scientific Advisory Board, Lymphoma Research Foundation since 2001.He had been the external Board of Director of Morphosys since 2016, and he serves as Board Director of the company since March 2019.|
|Eiji Ebinuma graduated from the Faculty of Law, the University of Tokyo in 1980, and completed a Master's degree in law at Sophia University. He joined The Industrial Bank of Japan, Limited (currently Mizuho Bank Ltd.) in 1980 and was promoted to Deputy Head of HR Planning Team of Mizuho Bank, Ltd (2002). In 2003, he became Head of Executive Secretary and General Planning Dept. of Olimpic Corporation. He received his attorney certification and joined Toranomon Sougoh Law Firm in 2008, and he has been a partner at Tanabe & Partners since 2013. He had been a Board Director of Mirait Holdings in 2014, and currently a Board Director of Rakuten Bank Ltd, and Auditor of TOKO ELECTRICAL CONSTRUCTION CO. He has been an Audit & Supervisory Board Member of the company since March 2019. He serves as Board Director of the company since March 2021.|
Full-Time Audit & Supervisory Board Member<Outside>
|Kiyoshi Watanabe graduated from Hitotsubashi University Faculty of Commerce and Management in 1974, and then joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.). He completed a Master's degree (MSM) at Purdue University Krannert School of Management. After serving as Chief of The Americas Corporate Credit Office, Credit Department of the Bank from 1998 in New York, he joined Kyowa Hakko Kogyo Co., Ltd. in 2003 as General Manager, Corporate Planning Office. He became General Manager, Medicine Planning Department of the Company in 2005, and then became General Manager, Planning and Administration Department at KYOWA HAKKO BIO CO., LTD. in 2008. He assumed the position of Full-time Audit & Supervisory Board Member at Kawaguchi Chemical Industry Co., Ltd. in 2011 and Audit & Supervisory Board Member at Toho Acetylene Co., Ltd., in 2015.|
Audit & Supervisory Board Member<Outside>
|Kesao Endo received his certification as a Certified Public Accountant in 1983. He joined Price Waterhouse Consultant in 1984. He joined Deloitte and Touche in 1986 and was stationed at Deloitte's Los Angeles and New York offices. He earned his USPCA (United States Certified Public Accountant) in 1991. He served as a member of the Audit & Supervisory Board at Akebono Brake Industry Co., Ltd in 2006. He currently serves outside director of Careerlink Co., Ltd. and is a partner of ABS Audit Corporation.|
Audit & Supervisory Board Member<Outside>
|Yasuhiro Tamo graduated from the Faculty of Law Class II of University of Tokyo in 2000, and then joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.). He transferred to Mizuho Corporate Bank, Ltd in 2002. He completed a Master's degree of Department of Legal Profession, Graduate School of Law, at Kyoto University in 2006. He joined Yanagida & Nomura (currently Yanagida ＆ Partners) in 2007, then moved to Nomura & Partners in 2009. He completed LL.M. at University of Michigan Law School in 2016. He has been a partner at Nomura & Partners since 2019, and he serves as Audit & Supervisory Board Member since March 2021.|